Theravance Biopharma (TBPH) EPS (Diluted) Growth (1y) (2018 - 2026)
Theravance Biopharma (TBPH) EPS (Diluted) Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,091.12% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 61.58% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -7.16% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 114.31% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 64.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.52% |
| Dec 31, 2025 | 274.98% |
| Sep 30, 2025 | 126.89% |
| Jun 30, 2025 | 418.81% |
| Mar 31, 2025 | -13.09% |
| Dec 31, 2024 | -231.49% |
| Sep 30, 2024 | -51.49% |
| Jun 30, 2024 | -22.85% |
| Mar 31, 2024 | 29.90% |
| Dec 31, 2023 | -281.22% |
| Sep 30, 2023 | -101.39% |
| Jun 30, 2023 | -214.54% |
| Mar 31, 2023 | -266.31% |
| Dec 31, 2022 | -85.74% |
| Sep 30, 2022 | 4,284.34% |
| Jun 30, 2022 | 27.09% |
| Mar 31, 2022 | 96.21% |
| Dec 31, 2021 | 130.75% |
| Sep 30, 2021 | 124.07% |
| Jun 30, 2021 | 118.95% |